Urinary Incontinence, Stress Clinical Trial
Official title:
A 3 Years Naturalistic Cohort Survey of Altis Single Incision Sling System For Female Stress Urinary Incontinence A Post-marketing and Multicenter Prospective Observational Cohort Study in Subjects With Female Stress Urinary Incontinence
Verified date | March 2022 |
Source | Coloplast A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The purpose of this study is to monitor the use of Altis Single Incision Sling (SIS) in a real world population and collect medical data on effectiveness and to monitor safety of Altis SIS at 12 and 36 months post device implantation in women with stress urinary incontinence.
Status | Active, not recruiting |
Enrollment | 599 |
Est. completion date | September 22, 2023 |
Est. primary completion date | September 22, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Implanted with Altis Single Incision Sling System Exclusion Criteria: - Refuses to be included in the survey or that their medical data will be used for research purposes - Indication for Altis Single Incision Sling System implantation is not for the treatment of female urinary incontinence. |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Leuven | Leuven | |
France | CHRU Hotel Dieu | Angers | |
France | Clinique Rhône Durance | Avignon | |
France | Clinique Champeau Mediterranée | Béziers | |
France | CHU Pellegrin-Urology Departement | Bordeaux | |
France | CHU Pellegrin_Gyneacology Departement | Bordeaux | |
France | Polyclinique Jean Villars | Bruges | |
France | Hôpital du Pays d'Autan | Castres | |
France | Pôle Santé Léonard de Vinci | Chambray-lès-Tours | |
France | CHU Clermont Ferrand | Clermont-Ferrand | |
France | Hôpital Victor Jousselin | Dreux | |
France | CH Paul Ardier | Issoire | |
France | Clinique Saint-Charles | La Roche sur Yon | |
France | Centre Hospitalier Saint Louis | La Rochelle | |
France | Clinique du Mail La Rochelle | La Rochelle | |
France | Clinique Saint-Amé | Lambres lez douai | |
France | CH Libourne | Libourne | |
France | Clinique Mutualiste de la Porte de l'Orient | Lorient | |
France | Hôpital privé Jacques Cartier | Massy | |
France | Armand Brillart Hospital | Nogent-sur-Marne | |
France | CHI Poissy Saint Germain en Laye | Poissy | |
France | Clinique St Hilaire | Rouen | |
France | Centre Clinical | Soyaux | |
France | Clinique Ambroise Paré | Toulouse | |
France | Clinique Saint Jean Languedoc | Toulouse | |
Germany | Frauenärzte im Seenland | Gunzenhausen | |
Germany | Klinikum Memmingen | Memmingen | |
Germany | Klinikum Worms gGmbH | Worms | |
Italy | Azienda USL Valle d'Aosta | Aosta | |
Spain | Hospital Vall d'Hebron | Barcelona | |
Spain | Hospital Univeritario Joan XXIII | Tarragona | |
Spain | Hospital la Fé | Valencia | |
Spain | Hosital Clinico de Valladolid | Valladolid |
Lead Sponsor | Collaborator |
---|---|
Coloplast A/S |
Belgium, France, Germany, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient Global Impression of Improvement (PGI-I) | PGI-I is a validated question that collects the patient's impression of improvement after the surgery. Among this 7 point-scale (very much better, much better, a little better, no change, a little worse, much worse and very much worse), the patients are asked to check the one number that describes how their urinay tract condition is now, compared with how it's was before the surgery. Patients who score little or much or very much better without serious or severe related adverse events will be considered a treatment success. The percentage of patients who describe the treatment success is measured | 12 months | |
Primary | Adverse events | Adverse events are any toward medical occurrence, unintended disease or injury or any untoward clinical signs in subjects. Adverse events will be categorized according to relatedness to device or procedure, severity and frequency. At 12-months, The percentage of patients without any device related severe or serious adverse events is measured. | 12 months | |
Secondary | Cough stress test (CST) | CST provides the means for documenting stress urinary incontinence. CST is considered "positive" if any leakage is noted with cough or valsava. The percentage of patients with positive and negative test will be calculated at baseline, at the post-operative visit and at one year | Baseline, 8 weeks and 12 months | |
Secondary | Post-void residual (PVR) volume | PVR volume will be collected pre- and post implant procedure up to 12 months. If the PVR volume is considered normal by the physician after the procedure it is not necessary to collect these data at the subsequent follow-up visits. | Baseline, 8 weeks and 12 months | |
Secondary | Pad Use | The number of pads used will be collected. Patients will be considered to be pad free if they report never wearing pads or wear pads just for a sense of security. | Baseline, 8 weeks, 12, 24 and 36 months | |
Secondary | International Consultation on Incontinence Questionnaire (ICIQ-UI) | The ICIQ-UI Short Form is a seft-administred questionnaire to evaluate the frequency, severity and impact on quality of life of urinary incontinence. Question 1 asked, "How often do you leak urine?" Subjects were instructed to select among "none" (0), "about once a week or less often" (1), "2 or 3 times a week" (2), "about once a day" (3), "several times a day" (4), and "all the time" (5). Question 2 asked, "How much urine do you usually leak (whether you wear protection or not)?" Patients responded with "none" (0), "a small amount" (2), "a moderate amount" (4) or "a large amount (6). Question 3 asked, "Overall, how much does leaking urine interfere with your everyday life?" Participants chose a number from 0 (not at all) to 10 (a great deal). Question 1, 2 and 3 are summed to compute the total ICIQ score.The total score range is then a minimum of 0 to a maximum of 21. The mean score, aboslute and relative change compared to baseline will be measure | Baseline, 8 weeks, 12, 24 and 36 months | |
Secondary | Subject global satisfaction questionnaire | This non-validated questionnaire provides additional information concerning patient satisfaction. This survey consists of two questions: Question 1 "how satisfied are you with your surgery?". Among 5 point-scale (very satisfied, satisfied, not satisfied-not dissatisfied, dissatisfied and very dissatified), patient check the one items that best describes the subject satisfaction. We measure the percentage the patients who very satisfied and satisfied. The patients answer the question "Do you recommend this operation to a friend?" by "yes" or "no". We measure the percentage of patients who answer "yes". | 8 weeks, 12, 24, 36 months | |
Secondary | Incontinence quality of life questionnaire (I-QoL) | The Incontinence quality of life questionnaire (I-QoL) is a validated survey questionnaire with 22 items that are scored on a 5-point Likert scale. The I-QOL ans its subcale scores are computed by adding each item's reponse, subtracting the lowest possible score and diving that sum by the possible raw score range. The scores are then transformed to have a range from 0 (maximum problem) to 100 (no problem at all). The mean score, absolute and relative change compared to baseline | Baseline, 8 weeks, 12, 24, 36 months | |
Secondary | Impact on sexual function assessed by the Pelvic organ/urinary incontinence sexual questionnaire (PISQ 12) | The Pelvic organ/urinary incontinence sexual questionnaire (PISQ-12) is a validated and reliable short form questionnaire including 12 questions that evaluates sexual function in heterosexual women with urinary incontinence and/or pelvic oragn prolapse. Reponses are graded on a 5-point Likert scale from "never" to "always". The scores will be calculated at each assessment visit. The mean score, absolute and relative change compared to baseline | Baseline, 8 weeks, 12, 24, 36 months | |
Secondary | Patient Global Impression of Improvement (PGI-I) | PGI-I is a validated question that collects the patient's impression of improvement after the surgery. Among this 7 point-scale (very much better, much better, a little better, no change, a little worse, much worse and very much worse), the patients are asked to check the one number that describes how their urinay tract condition is now, compared with how it's was before the surgery. The percentage of patients who describe very much better or much better or little better is measured | 8 weeks, 24, 36 months | |
Secondary | Adverse events | Adverse events are any toward medical occurrence, unintended disease or injury or any untoward clinical signs in subjects. Adverse events will be categorized according to relatedness to device or procedure, severity and frequency. The percentage of patients without any device related severe or serious adverse events is measured. | 8 weeks, 24, 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02001714 -
Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms
|
N/A | |
Not yet recruiting |
NCT00523068 -
Pharmacological vs Surgical Treatment for Mixed Incontinence
|
Phase 4 | |
Completed |
NCT00904969 -
A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence
|
N/A | |
Completed |
NCT00190827 -
Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)
|
Phase 3 | |
Completed |
NCT00190814 -
Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.
|
Phase 3 | |
Terminated |
NCT00247286 -
Weighted Vaginal Cones Versus Biofeedback in the Treatment of Urodynamic Stress Incontinence: a Randomized Trial.
|
Phase 4 | |
Completed |
NCT01959347 -
Combined Treatment for Mixed Incontinence
|
Phase 3 | |
Completed |
NCT00244296 -
To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms
|
Phase 4 | |
Not yet recruiting |
NCT05570071 -
A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI.
|
N/A | |
Completed |
NCT02334878 -
Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence
|
Phase 3 | |
Completed |
NCT01382602 -
Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
|
Phase 3 | |
Completed |
NCT03296462 -
Hip External Rotation Physical Therapy Trial
|
N/A | |
Recruiting |
NCT02750878 -
Surgical Consent Process for Trans-obturator Tape Slings.
|
N/A | |
Completed |
NCT02296099 -
Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence
|
Phase 4 | |
Completed |
NCT02599051 -
Transobturator Verus Single Incision Slings
|
N/A | |
Completed |
NCT00138749 -
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
|
Phase 2 | |
Terminated |
NCT03614611 -
Canadian Experience With Contiform Intravaginal Device For The Treatment Of Stress Incontinence
|
N/A | |
Completed |
NCT03722719 -
The Knack on Female Stress Urinary Incontinence
|
N/A | |
Active, not recruiting |
NCT02275728 -
Pelvic Floor Muscle Training With and Without Biofeedback in Women With Stress Urinary Incontinence
|
N/A | |
Terminated |
NCT01358214 -
Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)
|
N/A |